Pembrolizumab for the first-line treatment of non-small cell lung cancer

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

(2018) Gilberto Lopes et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

(2018) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly

(2017) Assunta Sgambato et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

(2017) Julie R Brahmer et al.   LANCET ONCOLOGY

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

(2017) Randy F. Sweis et al.   PHARMACOLOGICAL RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

(2016) Kurt A. Schalper et al.   CLINICAL CANCER RESEARCH

Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

(2016) Cesare Gridelli et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Pembrolizumab for the treatment of non-small cell lung cancer

(2016) Sung Hee Lim et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody

(2016) Nobuaki Mamesaya et al.   INVESTIGATIONAL NEW DRUGS

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

(2015) Kiichiro Ninomiya et al.   International Journal of Clinical Oncology

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Mechanism of Action of Immunotherapy

(2014) Mary L. Disis   SEMINARS IN ONCOLOGY

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002

(2013) Katsuyuki Hotta et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA